Virios Therapeutics, Inc. (VIRI)
NASDAQ: VIRI · IEX Real-Time Price · USD
0.456
+0.031 (7.20%)
At close: Apr 25, 2024, 4:00 PM
0.452
-0.004 (-0.90%)
After-hours: Apr 25, 2024, 6:40 PM EDT
Virios Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Virios Therapeutics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for VIRI.
Recommendation Trends
Rating | Jul '22 | Aug '22 | Sep '22 |
---|---|---|---|
Strong Buy | 1 | 1 | 0 |
Buy | 0 | 0 | 0 |
Hold | 0 | 0 | 0 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 1 | 1 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 20, 2022 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Dec 15, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.28
from -0.28
EPS Next Year
-0.31
from -0.28
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | 17.6M | 71.9M |
Avg | n/a | n/a | n/a | 17.1M | 69.9M |
Low | n/a | n/a | n/a | 16.5M | 67.1M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 319.6% |
Avg | - | - | - | - | 307.6% |
Low | - | - | - | - | 291.6% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.18 | -0.29 | -0.51 | -0.76 | -0.05 |
Avg | -0.28 | -0.31 | -0.50 | -0.73 | -0.05 |
Low | -0.36 | -0.31 | -0.48 | -0.71 | -0.05 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.